background
avail
diagnost
often
fail
distinguish
viral
bacteri
caus
pediatr
communityacquir
pneumonia
pcap
metabolom
aim
character
diseas
base
metabol
signatur
appli
expand
pathophysiolog
understand
mani
diseas
exploratori
studi
use
untarget
metabolom
analysi
shed
new
light
etiolog
pcap
method
liquid
chromatographi
coupl
mass
spectrometri
use
quantifi
metabolit
content
urin
sampl
collect
children
hospit
cap
pneumococc
viral
etiolog
ascertain
use
conserv
algorithm
combin
microbiolog
biochem
data
result
fiftynin
children
cap
enrol
month
pneumococc
viral
case
distinguish
mean
multivari
model
base
metabolit
identifi
consid
put
biomark
among
six
metabolit
belong
adren
steroid
synthesi
degrad
pathway
conclus
preliminari
studi
suggest
viral
pneumococc
pneumonia
differ
affect
system
metabolom
stronger
disrupt
adren
steroid
pathway
pneumococc
pneumonia
find
may
lead
discoveri
novel
diagnost
biomark
bring
us
closer
person
therapi
pcap
bacteri
biomark
cap
mass
spectrometri
pcap
viral
communityacquir
pneumonia
cap
singl
common
caus
death
among
children
worldwid
lead
caus
hospit
although
bodi
knowledg
epidemiolog
etiolog
microbiolog
pathophysiolog
cap
expand
last
decad
basic
patient
manag
question
remain
larg
unansw
fact
confront
feverish
child
respiratori
symptom
singl
import
manag
question
whether
start
antibiot
translat
confid
treat
physician
child
question
bacteri
lower
respiratori
tract
infect
although
epidemiolog
research
repeatedli
point
larg
major
lower
respiratori
infect
pediatr
patient
caus
virus
physician
often
lack
tool
reliabl
discrimin
bacteri
viral
etiolog
larg
percentag
children
present
respiratori
symptom
fever
ultim
administ
antibiot
absenc
certainti
regard
cap
etiolog
thu
prompt
overtreat
consequ
increas
emerg
bacteri
resist
metabolom
newest
branch
system
biolog
approach
biomed
research
aim
provid
unabridg
descript
qualit
quantit
metabolit
ie
molecul
molecular
weight
less
da
found
human
biofluid
tissu
given
time
word
aim
defin
particular
metabol
signatur
fingerprint
character
diseas
state
power
analyt
tool
use
amass
larg
amount
data
analyz
appli
previouslyunsolv
complex
question
biolog
particular
metabolom
provid
comprehens
overview
pathophysiolog
identifi
new
biomark
use
diagnost
point
potenti
therapeut
target
consid
search
new
drug
present
exploratori
investig
hypothesisfre
approach
base
untarget
metabolom
appli
pediatr
cap
pcap
effort
improv
diagnosi
clinic
manag
common
childhood
infect
specif
studi
aim
elucid
whether
specif
metabol
signatur
differenti
pneumococc
viral
pcap
studi
approv
institut
ethic
committe
written
inform
consent
sign
parent
requir
child
includ
studi
children
age
year
older
written
inform
assent
also
requir
case
elig
studi
hospit
children
less
year
age
diagnosi
moder
sever
pneumonia
diagnosi
cap
base
clinic
present
presenc
fever
symptom
suggest
acut
respiratori
ill
defin
new
cough
sputum
product
chest
pain
dyspnea
tachypnea
abnorm
lung
examin
chest
xray
result
chest
xray
evalu
blind
radiologist
studi
particip
decis
admit
child
hospit
cap
made
attend
physician
emerg
depart
increas
specif
find
reduc
role
confound
variabl
three
exclus
criteria
strictli
appli
concern
infant
ie
children
year
age
avoid
diagnost
overlap
pneumonia
bronchiol
children
previou
diagnosi
chronic
diseas
hiv
asthma
immunodefici
chd
reduc
pathophysiolog
heterogen
cap
case
children
given
oral
inject
antibiot
therapi
hour
preced
enrol
avoid
case
partial
treat
pneumonia
relat
pathophysiolog
profil
differ
lung
infect
devoid
treatment
pharmacolog
treatment
recruit
subject
monitor
hospit
evalu
potenti
confound
effect
find
threestep
algorithm
combin
microbiolog
inform
obtain
pcr
assay
pct
level
use
ascertain
pneumonia
etiolog
subsequ
metabolom
analysi
three
variabl
consid
sequenti
presenc
absenc
respiratori
virus
reveal
multiplex
pcr
assay
presenc
absenc
pneumonia
pcr
assay
pct
cutoff
ngml
use
algorithm
viral
etiolog
assum
presenc
respiratori
virus
absenc
pneumonia
pct
ngml
pneumococc
etiolog
assum
absenc
respiratori
virus
presenc
pneumonia
pct
ngml
case
fall
either
categori
label
undetermin
includ
subsequ
analysi
strategi
appli
obtain
pure
group
metabolom
investig
limit
number
falseposit
case
ie
case
inconsist
result
pct
measur
pcr
analysi
exclud
subclass
analysi
tabl
contain
clinic
demograph
characterist
patient
search
avail
onlin
metabolit
databas
gener
put
identif
variabl
tabl
pneumonia
pleural
infect
probabl
consequ
aggress
metabol
activ
amino
acid
biosynthesi
induc
pneumonia
replic
cyclic
guanosin
monophosph
cgmp
next
signific
molecul
emerg
analysi
mediat
mani
proinflammatori
antiinflammatori
function
nitric
oxid
tolllik
receptor
ligand
induc
express
cgmp
increas
activ
synthetas
fact
endotoxin
infus
healthi
volunt
shown
rais
exhal
cgmp
plasma
concentr
bacteria
may
also
increas
synthesi
cgmp
produc
directli
studi
corrobor
previou
report
provid
evid
plausibl
use
metabolit
diagnost
marker
bacteri
infect
anoth
two
molecul
interest
discuss
acylcarnitin
sialyl
oligosaccharid
carnitin
metabol
tie
mitochondri
homeostasi
long
studi
context
sever
infect
septic
patient
show
mani
abnorm
lipid
metabol
includ
deplet
cellular
level
lcarnitin
reduct
plasma
level
increas
urinari
excret
three
recent
metabolom
studi
also
found
increas
urinari
concentr
acylcarnitin
patient
bacteri
pneumonia
inde
pneumococc
cytotoxin
pneumolysin
caus
mitochondri
damag
may
account
observ
disarray
lipid
metabol
sialyl
oligosaccharid
broken
digest
lysosom
rel
increas
sialyl
oligosaccharid
cours
bacteri
infect
may
repres
transient
lysosom
dysfunct
inde
role
lysosom
human
health
diseas
start
unveil
evid
alreadi
accumul
lysosom
serv
regul
macrophag
function
key
effector
pneumonia
intracellular
kill
recent
metaanalysi
transcriptom
studi
also
show
messeng
rna
pathway
associ
lysosom
function
among
profoundli
disrupt
cours
human
sepsi
short
studi
point
organel
dysfunct
crucial
discrimin
bacteri
viral
infect
viral
pneumonia
associ
increas
urin
concentr
glycyllhydroxyprolin
glypro
end
product
collagen
metabol
substrat
enzym
prolidas
promot
surfac
express
interferoni
receptor
target
viral
antagon
higher
urinari
level
glypro
found
studi
may
therefor
reflect
impair
prolidas
activ
could
expect
cours
viral
infect
although
stateoftheart
highthroughput
analyt
method
chemometr
data
process
method
use
studi
weak
import
concern
fact
collect
sampl
therapyna
patient
constitut
verit
sourc
bia
issu
could
avoid
collect
urin
sampl
therapyna
children
present
emerg
depart
respiratori
symptom
fever
analyz
obtain
children
actual
enrol
studi
worth
bear
mind
futur
metabolom
studi
conduct
acut
care
set
anoth
weak
studi
concern
small
number
patient
two
group
may
limit
valid
find
hand
adopt
stringent
enrol
criteria
conserv
diagnost
algorithm
ensur
two
group
etiolog
pure
thu
enhanc
specif
find
potenti
limit
exploratori
studi
lie
lack
extern
valid
set
test
model
could
valid
intern
mean
crossvalid
stabil
select
ensur
reliabl
find
emerg
data
collect
though
preliminari
studi
present
find
seem
promis
start
point
conduct
larger
valid
studi
